Search
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Foralumab
go.drugbank.com/drugs/DB16170InvestigationalForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Strontium malonate
go.drugbank.com/drugs/DB05732InvestigationalStrontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Human umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalTransplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs’ differentiation potential, the growth fact...
INCB-9471
go.drugbank.com/drugs/DB12960InvestigationalINCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.
Nicaraven
go.drugbank.com/drugs/DB06397ExperimentalCategories: Compounds used in a research, industrial, or household settingImisopasem manganese
go.drugbank.com/drugs/DB04976InvestigationalM40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
DDP-225
go.drugbank.com/drugs/DB05642InvestigationalDDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.